|
1.
|
2026/06/20
|
|
Japanese clinical practice guidelines for pharmacotherapy in older adults with cancer (second edition): an overview
|
|
2.
|
2026/04/11
|
|
Delayed Gastric Bleeding in a Patient With Chronic Myeloid
Leukemia: A Case of Post-Biopsy Bleeding
|
|
3.
|
2026/03/14
|
|
Bridging therapy with airway stent placement followed by immune checkpoint inhibitors in patients with lung cancer and malignant airway disorders: A retrospective study
|
|
4.
|
2026/02/11
|
|
Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment
|
|
5.
|
2026/01/19
|
|
Effectiveness of Balloon Dilatation for Bronchoscope Delivery Using
the SUKEDACHI Balloon with an Ultrathin Bronchoscope for Subpleural
Pulmonary Nodule Diagnosis: A Case Series of Three Patients
|
|
6.
|
2025/11
|
|
Impact of antibiotic use on survival in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor and chemotherapy
|
|
7.
|
2025/10/16
|
|
Acute Radiation Esophagitis After Chemoradiotherapy Demonstrating "Tube-Like" FDG Uptake on PET-CT: Case Report and Literature Review
|
|
8.
|
2025/09/08
|
|
Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung Cancer
|
|
9.
|
2025/08/01
|
|
Influence of Primary Care Physicians on End-of-Life Treatment Choices in Lung Cancer Diagnosed in the Emergency Department.
|
|
10.
|
2025/07/28
|
|
Utility of ultrasound-guided transbronchial needle biopsy using an acquire needle in the diagnosis of chest and mediastinal diseases
|
|
11.
|
2025/05/31
|
|
Plasma biomarkers for afatinib monotherapy in EGFR-mutated non-small cell lung cancer: Novel insights from companion genomics analysis of the EXTRA study
|
|
12.
|
2025/04/25
|
|
Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer
|
|
13.
|
2025/03/19
|
|
Establishment and characterization of novel patient-derived esophageal tumoroids with long-term cultivability
|
|
14.
|
2025/01/31
|
|
The heterogeneity in oligoprogression and stereotactic body radiation therapy
|
|
15.
|
2024/12
|
|
Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study
|
|
16.
|
2024/11/16
|
|
Four cases with FUS/CHOP fusion gene products positive myxoid liposarcoma responding effectively to trabectedin monotherapy
|
|
17.
|
2024/10
|
|
A case of primary duodenal Brunner's gland hamartoma that gradually underwent morphological changes over a period of ten years
|
|
18.
|
2024/07/19
|
|
The combined inhibition of SLC1A3 and glutaminase in osimertinib-resistant EGFR mutant cells
|
|
19.
|
2024/07
|
|
Establishment and characterization of novel high mucus‑producing lung tumoroids derived from a patient with pulmonary solid adenocarcinoma
|
|
20.
|
2024/06/03
|
|
Transforming tumoroids derived from ALK‑positive pulmonary
adenocarcinoma to squamous cell carcinoma in vivo
|
|
21.
|
2024/04/28
|
|
Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies
|
|
22.
|
2024/03/05
|
|
Endobronchial Ultrasonography With Guide Sheath for the Diagnosis of Peripheral Pulmonary Lesions in Japan: A Literature Review
|
|
23.
|
2024/03/01
|
|
The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics
|
|
24.
|
2024/02/12
|
|
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study
|
|
25.
|
2024/02/08
|
|
Pneumocystis jirovecii pneumonia mortality risk associated with preceding long-term steroid use for the underlying disease: A multicenter, retrospective cohort study
|
|
26.
|
2023/06/05
|
|
Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study
|
|
27.
|
2023/04/25
|
|
Chest computed-tomography 1 day before the diagnosis of coronavirus disease 2019
|
|
28.
|
2023/03/01
|
|
The complexity of EGFR exon 19 deletion and L858R mutant cells as assessed by proteomics, transcriptomics, and metabolomics
|
|
29.
|
2023/02
|
|
Effect of a Cyclooxygenase-2 Inhibitor in Combination with (-)-Epigallocatechin Gallate or Polyphenon E on Cisplatin-Induced Lung Tumorigenesis in A/J Mice
|
|
30.
|
2023/01
|
|
Safe sedation during diagnostic and therapeutic flexible bronchoscopy in Japan: A review of the literature
|
|
31.
|
2022/05/12
|
|
Use of a highly sensitive lung cancer compact panel to detect KRAS G12D in the wash fluid from a lung tumor: A case report
|
|
32.
|
2022/04/06
|
|
First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study
|
|
33.
|
2022/03/31
|
|
Herpes zoster in lung cancer patients treated with PD-1/PD-L1
inhibitors
|
|
34.
|
2021/11/20
|
|
Oligoprogression in Non-Small Cell Lung Cancer
|
|
35.
|
2021/08/02
|
|
End-tidal capnographic monitoring during flexible bronchoscopy under fentanyl and midazolam sedation
|
|
36.
|
2021/06/03
|
|
IgA Vasculitis in a Lung Cancer Patient During Chemoradiotherapy
|
|
37.
|
2021/05
|
|
Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial
|
|
38.
|
2021/05
|
|
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression
|
|
39.
|
2021/03/01
|
|
A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401
|
|
40.
|
2021/01/20
|
|
Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial
|
|
41.
|
2020/07
|
|
Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?
|
|
42.
|
2020/04/09
|
|
Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab following Tubulointerstitial Nephritis due to Pembrolizumab.
|
|
43.
|
2020/01
|
|
Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.
|
|
44.
|
2019/12/02
|
|
De Novo Carborane-Containing Macrocyclic Peptides Targeting Human Epidermal Growth Factor Receptor.
|
|
45.
|
2019/08
|
|
A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.
|
|
46.
|
2019/07
|
|
Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia.
|
|
47.
|
2019/05
|
|
Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities.
|
|
48.
|
2019/02
|
|
Chemoradiotherapy for locally advanced lung cancer patients with interstitial lung abnormalities.
|
|
49.
|
2019
|
|
悪性中皮腫細胞株に対する新規signal transducer and activator of transcription 3阻害剤BBI608(A new signal transducer and activator of transcription 3 inhibitor, BBI608, in malignant mesothelioma cell lines)
|
|
50.
|
2018/12
|
|
Blocking both epidermal growth factor receptor and mesenchymal-to-epithelial transition pathways in EGFR-mutated lung cancer
|
|
51.
|
2018/11
|
|
Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry.
|
|
52.
|
2018/10
|
|
"A phase II trial of EGFR-TKI readministration with afatinib in advanced
non-small-cell lung cancer harboring a sensitive non-T790M EGFR
mutation: Okayama Lung Cancer Study Group trial 1403"
|
|
53.
|
2018/10
|
|
Acute necrotizing encephalopathy in an adult with influenza A infection.
|
|
54.
|
2018/10
|
|
Descending necrotizing mediastinitis in a healthy young adult.
|
|
55.
|
2018/10
|
|
How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?
|
|
56.
|
2018/08
|
|
Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: A comparison of serum Krebs von Lungen-6 and Thymus and Activation-Regulated Chemokine/CC Chemokine Ligand 17
|
|
57.
|
2018/08
|
|
Erythema as a Visual Surrogate Marker of Glucagonoma
|
|
58.
|
2018/08
|
|
Histology versus cytology: PD-L1 testing in non-small cell lung cancer
|
|
59.
|
2018/07
|
|
"Engagement ring" image conveys regrettable outcome for aged patients with non-small cell lung cancer.
|
|
60.
|
2018/07
|
|
Needle wash solution cultures following EBUS-TBNA with or without endobronchial intubation.
|
|
61.
|
2018/06
|
|
Development of an integrated CRISPRi targeting Np63 for treatment of squamous cell carcinoma.
|
|
62.
|
2018/03
|
|
Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery.
|
|
63.
|
2018/02
|
|
Patients with osteosarcoma and soft tissue sarcoma might become"cancer refugee" in some Japanese regional cities
|
|
64.
|
2018/01
|
|
A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
|
|
65.
|
2018/01
|
|
Accidental aspiration of denture cleanser tablets caused severemucosal edema in upper airway.
|
|
66.
|
2017/12
|
|
Ceftriaxone-associated pancreatitis captured on serial computed tomography scans.
|
|
67.
|
2017/12
|
|
Effects of (-)-epigallocatechin-3-gallate on EGFR- or fusion gene-driven lung cancer cells.
|
|
68.
|
2017/11
|
|
Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma.
|
|
69.
|
2017/10
|
|
A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202.
|
|
70.
|
2017/10
|
|
Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma.
|
|
71.
|
2017/05
|
|
Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study.
|
|
72.
|
2017/04
|
|
What can we learn from 3 phase III trials of ASCEND-4: ceritinib vs. platinum/pemetrexed with pemetrexed maintenance, PROFILE 1004: crizotinib vs. platinum/pemetrexed, and J-ALEX: alectinib vs. crizotinib?
|
|
73.
|
2017/03
|
|
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
|
|
74.
|
2016/11
|
|
Gynecomastia as a paraneoplastic symptom of choriocarcinoma
|
|
75.
|
2016/11
|
|
High uptake of Fluorodeoxy glucose along biliary stent
|
|
76.
|
2016/11
|
|
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
|
|
77.
|
2016/11
|
|
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405)
|
|
78.
|
2016/10
|
|
MET-inhibitors meet MET mutations in lung cancer.
|
|
79.
|
2016/08
|
|
A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.
|
|
80.
|
2016/08
|
|
Cytomegalovirus Colitis in a Lung Cancer Patient.
|
|
81.
|
2016/08
|
|
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation
|
|
82.
|
2016/07
|
|
Safety and discomfort during bronchoscopy performed under sedation with fentanyl and midazolam: a prospective study.
|
|
83.
|
2016/06
|
|
Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
|
|
84.
|
2016/06
|
|
Herpetic esophagitis following bendamustine-containing regimen
|
|
85.
|
2016/05
|
|
Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
|
|
86.
|
2016/02
|
|
Dropped head syndrome following mantle radiation therapy
|
|
87.
|
2016/02
|
|
SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma
|
|
88.
|
2016/01
|
|
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
|
|
89.
|
2015/11
|
|
PET superscan caused by lung cancer
|
|
90.
|
2015/10
|
|
Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model
|
|
91.
|
2015/10
|
|
Progressive paraplegia caused by recurrence of mantle cell lymphoma with atypical spinal magnetic resonance imaging features
|
|
92.
|
2015/09
|
|
Successful palliation for an aged patient with primary pericardial mesothelioma
|
|
93.
|
2015/08
|
|
Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.
|
|
94.
|
2015/06
|
|
Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study
|
|
95.
|
2015/06
|
|
Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines
|
|
96.
|
2015/06
|
|
Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain.
|
|
97.
|
2015/05
|
|
Endobronchial ultrasound-guided transbronchial biopsy with or without a guide sheath for diagnosis of lung cancer.
|
|
98.
|
2015/04
|
|
Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer.
|
|
99.
|
2015/04
|
|
Non-occlusive mesenteric ischemia after splenic metastasectomy for small-cell lung cancer
|
|
100.
|
2015/01
|
|
Cisplatin-induced hyponatremia in malignancy:comparison between brand-name and generic formulation
|
|
101.
|
2014/11
|
|
A phase II study of S-1 chemotherapy with concurrent thoracic radiotherapy in elderly patients with locally advanced non-small-cell lung cancer: The Okayama Lung Cancer Study Group Trial 0801
|
|
102.
|
2014/11
|
|
Skin involvement in diffuse large B-cell lymphoma detected using positron emission tomography
|
|
103.
|
2014/10
|
|
A New Human Lung Adenocarcinoma Cell Line Harboring the EML4-ALK Fusion Gene
|
|
104.
|
2014/10
|
|
Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma.
|
|
105.
|
2014/08
|
|
A case of autoimmune pulmonary alveolar proteinosis appearing as a localized ground-glass opacity.
|
|
106.
|
2014/08
|
|
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors
|
|
107.
|
2014/05
|
|
Epiphora in lung cancer patients receiving docetaxel: a case series.
|
|
108.
|
2014/05
|
|
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience
|
|
109.
|
2014/05
|
|
Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinoma.
|
|
110.
|
2014/05
|
|
Neurogenic Pulmonary Edema After Subarachnoid Hemorrhage.
|
|
111.
|
2014/03
|
|
Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer
|
|
112.
|
2014/03
|
|
The Role of STAT3 in Non-Small Cell Lung Cancer
|
|
113.
|
2014/02
|
|
Guidelines for Long-Term Steroid Therapy In End-Of-Life Palliative Care
|
|
114.
|
2014/02
|
|
Vaccination With NY-ESO-1 Overlapping Peptides Mixed With Picibanil OK-432 and Montanide ISA-51 in Patients With Cancers Expressing the NY-ESO-1 Antigen
|
|
115.
|
2014/01
|
|
Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model
|
|
116.
|
2014/01
|
|
Fibrin sheath following pleurodesis
|
|
117.
|
2014/01
|
|
Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas
|
|
118.
|
2014/01
|
|
Rapid on-site evaluation with BIOEVALUATOR during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing pulmonary and mediastinal diseases
|
|
119.
|
2013/11
|
|
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model
|
|
120.
|
2013/11
|
|
Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002
|
|
121.
|
2013/11
|
|
Successful treatment of a lung cancer patient with factor XI deficiency
|
|
122.
|
2013/11
|
|
Usefulness of endobronchial ultrasound-guided transbronchial needle aspiration in distinguishing sarcoidosis from recurrent cancer in patients with lymphadenopathy after surgery
|
|
123.
|
2013/09
|
|
Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations
|
|
124.
|
2013/08
|
|
Antitumor Impact of p14ARF on Gefitinib-Resistant Non-Small Cell Lung Cancers
|
|
125.
|
2013/08
|
|
Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancers
|
|
126.
|
2013/07
|
|
Methotrexate-induced lymphoproliferative disease: Epstein-Barr virus associated lymphomatoid granulomatosis
|
|
127.
|
2013/05
|
|
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells
|
|
128.
|
2013/05
|
|
Afatinib prolongs survival compared to gefitinib in an epidermal growth factor receptor-driven lung cancer model
|
|
129.
|
2013/05
|
|
Thickened colon wall in follicular lymphoma
|
|
130.
|
2013/04
|
|
Continuous pemetrexed treatment for brain metastasis in non-small cell lung cancer-A report of two cases
|
|
131.
|
2013/03
|
|
Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
|
|
132.
|
2013/03
|
|
Fatal interstitial pneumonia caused by panitumumab containing chemotherapy : a case report
|
|
133.
|
2013/02
|
|
Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells
|
|
134.
|
2013/02
|
|
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency
|
|
135.
|
2013/01
|
|
Antiproliferative effect of the HSP90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer
|
|
136.
|
2013/01
|
|
Can we eliminate squamous cell carcinoma of the lung from testing of EML4-ALK fusion gene?
|
|
137.
|
2013/01
|
|
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer
|
|
138.
|
2013/01
|
|
Subpopulation of small-cell lung cancer cells expressing CD133 and CD87 show resistance to chemotherapy
|
|
139.
|
2012/11
|
|
Elevated Coagulation Factor VIII Plasma Activity in a Patient with Lymphangiosarcoma
|
|
140.
|
2012/10
|
|
Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors
|
|
141.
|
2012/10
|
|
Influence of the timing of tumor regression after the initiation of chemoradiotherapy on prognosis in patients with limited-disease small-cell lung cancer achieving objective response
|
|
142.
|
2012/10
|
|
JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation
|
|
143.
|
2012/09
|
|
Spontaneous expectoration of tumor tissue in a patient with adenocarcinoma of the lung
|
|
144.
|
2012/08
|
|
Treatment-related death in patients with small-cell lung cancer in phase III trials over the last two decades
|
|
145.
|
2012/07
|
|
Clinical outcome in patients with leptomeningeal metastasis from non-small cell
lung cancer: Okayama Lung Cancer Study Group
|
|
146.
|
2012/07
|
|
Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402
|
|
147.
|
2012/06
|
|
Selective cyclooxygenase-2 inhibitor prevents cisplatin-induced tumorigenesis in A/J mice
|
|
148.
|
2012/05
|
|
Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.
|
|
149.
|
2012/04
|
|
Favorable Response of Heavily Treated Wilms' Tumor to Paclitaxel and Carboplatin
|
|
150.
|
2012/04
|
|
Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
|
|
151.
|
2012/03
|
|
Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.
|
|
152.
|
2012/03
|
|
Cytotoxicity of Activated Natural Killer Cells and Expression of Adhesion Molecules in Small-cell Lung Cancer
|
|
153.
|
2012/03
|
|
Stewart-Treves syndrome after cervical cancer
|
|
154.
|
2012/02
|
|
Ruptured littoral cell angiosarcoma causing hemoperitoneum.
|
|
155.
|
2012/01
|
|
STAT3 expression in activating EGFR-driven adenocarcinoma of the lung.
|
|
156.
|
2011/12
|
|
A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
|
|
157.
|
2011/12
|
|
Cavitary pulmonary involvement of diffuse large B-cell lymphoma transformed from extra nodal marginal zone B-cell lymphoma MALT type
|
|
158.
|
2011/11
|
|
Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
|
|
159.
|
2011/11
|
|
Variant angina pectoris associated with FOLFOX4 therapy
|
|
160.
|
2011/10
|
|
A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
|
|
161.
|
2011/10
|
|
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
|
|
162.
|
2011/10
|
|
Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.
|
|
163.
|
2011/10
|
|
Spontaneous regression of pulmonary pure ground-glass opacity with progression of a solid component during a 40-month follow-up
|
|
164.
|
2011/09
|
|
Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung.
|
|
165.
|
2011/09
|
|
Liposomal Delivery of MicroRNA-7-Expressing Plasmid Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells.
|
|
166.
|
2011/08
|
|
Medical Treatment of Mesothelioma: Anything New?
|
|
167.
|
2011/07
|
|
An oral fluoropyrimidine agent S-1 induced interstitial lung disease: A case report.
|
|
168.
|
2011/06
|
|
Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007.
|
|
169.
|
2011/05
|
|
Synchronous double primary lung cancers with different response to pemetrexed.
|
|
170.
|
2011/04
|
|
Cure- or care-oriented regimen for stage III non-small-cell lung cancer?
|
|
171.
|
2011/04
|
|
Migrating ground glass opacities on computed tomography due to gravitation in a patient with pulmonary alveolar proteinosis.
|
|
172.
|
2011/02
|
|
Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment.
|
|
173.
|
2011/01
|
|
A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer.
|
|
174.
|
2010/12
|
|
Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience.
|
|
175.
|
2010/10
|
|
Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705.
|
|
176.
|
2010/09
|
|
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
|
|
177.
|
2010/07
|
|
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
|
|
178.
|
2010/02
|
|
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
|
|
179.
|
2010/02
|
|
Obstructive jaundice at the initial presentation in small-cell lung cancer.
|
|
180.
|
2010/02
|
|
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
|
|
181.
|
2010/01
|
|
A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
|
|
182.
|
2010
|
|
Diffuse alveolar hemorrhage with chronic thyroiditis in an advanced-age adult.
|
|
183.
|
2009/11
|
|
Aspergilloma in a cavity formed after percutaneous radiofrequency ablation for lung cancer.
|
|
184.
|
2009/11
|
|
Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results.
|
|
185.
|
2009/10
|
|
Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.
|
|
186.
|
2009/09
|
|
Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.
|
|
187.
|
2009/09
|
|
Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.
|
|
188.
|
2009/07
|
|
A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.
|
|
189.
|
2009/07
|
|
Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment.
|
|
190.
|
2009/06
|
|
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.
|
|
191.
|
2009/04
|
|
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors.
|
|
192.
|
2009/03
|
|
Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer.
|
|
193.
|
2009/03
|
|
Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer.
|
|
194.
|
2009/01
|
|
Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.
|
|
195.
|
2009
|
|
A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization.
|
|
196.
|
2008/12
|
|
Paradoxical clinical effects of epidermal growth factor receptor-tyrosine kinase inhibitors for acute myelogenous leukemia.
|
|
197.
|
2008/11
|
|
Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer.
|
|
198.
|
2008/11
|
|
Synchronous pulmonary MALT lymphoma and pulmonary adenocarcinoma after metachronous gastric MALT lymphoma and gastric adenocarcinoma.
|
|
199.
|
2008/09
|
|
Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
|
|
200.
|
2008/04
|
|
Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine.
|
|
201.
|
2008/03
|
|
Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer.
|
|
202.
|
2008/02
|
|
Pseudoprogression of lung cancer after concomitant chemoradiotherapy.
|
|
203.
|
2008/01
|
|
Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
|
|
204.
|
2008/01
|
|
Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
|
|
205.
|
2007/11
|
|
Super scan using positron emission tomography in lung cancer patients.
|
|
206.
|
2007/10
|
|
Isolated metastasis of lung cancer to the thyroid gland.
|
|
207.
|
2007/10
|
|
Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.
|
|
208.
|
2007/10
|
|
Point mutation of K-ras gene in cisplatin-induced lung tumours in A/J mice.
|
|
209.
|
2007/09
|
|
Presentation of Garcin syndrome due to lung cancer.
|
|
210.
|
2007/08
|
|
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
|
|
211.
|
2007/08
|
|
Radiation necrosis mimicking progressive brain metastasis in a patient with non-small cell lung cancer.
|
|
212.
|
2007/08
|
|
Serum level of arginine-vasopressin influences the prognosis of extensive-disease small-cell lung cancer.
|
|
213.
|
2007/07
|
|
Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.
|
|
Display 5 items
|
|
Display all(213)
|
